NCT01600222已完成2 期
A Phase 2 Maximal Use Systemic Exposure (MUSE) Study Evaluating the Safety and Efficacy of LEO 90100 Used Once Daily in Subjects With Extensive Psoriasis Vulgaris
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- LEO Pharma
- 入组人数
- 37
- 试验地点
- 10
- 主要终点
- Change in Albumin-corrected Serum Calcium From Baseline to Day 28
研究概览
简要总结
A Phase 2 Maximal Use Systemic Exposure (MUSE) study evaluating the safety and efficacy of LEO 90100 used once daily in subjects with extensive psoriasis vulgaris.
详细描述
The purpose of the present study is to assess the systemic safety of LEO 90100. Although LEO 90100 contains the same active ingredients in the same concentration as DAIVOBET/DOVOBET/TACLONEX ointment, the degree of absorption of the active ingredients from the new formulation may differ. Systemic safety will be assessed through the effect of LEO 90100 on calcium metabolism and HPA axis function under maximum use conditions (i.e., in subjects with very extensive psoriasis on the trunk, limbs and scalp, using up to 120g per week of LEO 90100 for up to 4 weeks). Data from this study, together with the measurements of albumin-corrected serum calcium and the calcium:creatinine ratio in spot urine samples in the planned phase 2 and 3 studies in the development program for LEO 90100, are expected to provide adequate information with respect to the systemic safety of LEO 90100.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated informed consent obtained prior to any trial related activities (including any washout period)
- •Age 18 years or above
- •Either sex
- •Any race or ethnicity
- •Any skin type
- •Attending a hospital out-patient clinic or the private practice of a dermatologist for treatment of psoriasis vulgaris
- •At SV2 and Day 0 (Visit 1), a clinical diagnosis of psoriasis vulgaris of at least 6 months duration involving the trunk and/or limbs and the scalp which is;
- •amenable to topical treatment with a maximum of 120g of study medication per week
- •of an extent of between 15 and 30% of the body surface area (BSA) excluding psoriatic lesions of the face, genitals and skin folds
- •including at least 30% scalp involvement
- •of at least a moderate disease severity according to the investigators global assessment (IGA)
- •At SV2, a normal HPA axis function including a serum cortisol concentration above 5 mcg/dl before ACTH-challenge and above 18 mcg/dl 30 minutes after ACTH-challenge
- •At SV2, an albumin-corrected serum calcium below the upper reference range limit
- •At SV2, females of child-bearing potential must have a negative urine pregnancy result
- •Females of child-bearing potential must agree to use a highly effective method of contraception during the study. A highly effective method of birth control is defined as one which results in a low failure rate (less than 1% per year)
- •Able to communicate with the investigator and understand and comply with the requirements of the study
排除标准
- •A history of allergic asthma, serious allergy or serious allergic skin rash
- •Known or suspected hypersensitivity to component(s) of LEO 90100 or CORTROSYN (including cosyntropin/tetracosactide)
- •Systemic treatment with corticosteroids (including inhaled and nasal steroids) within 12 weeks prior to SV2
- •Systemic treatment with biological therapies (whether marketed or not marketed), with a possible effect on psoriasis vulgaris within the following time period prior to Day 0 (Visit 1);
- •etanercept - within 4 weeks
- •adalimumab, alefacept, infliximab - within 8 weeks
- •ustekinumab - within 16 weeks
- •other products - within 4 weeks/5 half-lives (whichever is longer)
- •Subjects who have received treatment with any non-marketed drug substance (i.e. a drug which has not yet been made available for clinical use following registration) within 4 weeks/5 half-lives (whichever is longer) prior to Day 0 (Visit 1)
- •Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g. retinoids, methotrexate, cyclosporine and other immunosuppressants) within 4 weeks prior to Day 0 (Visit 1)
- •PUVA therapy within 4 weeks prior to Day 0 (Visit 1)
- •UVB therapy within 2 weeks prior to day 0 (Visit 1).
- •Topical treatment with corticosteroids or vitamin D analogues on any body location within 2 weeks prior to SV2
- •Any topical treatment of psoriasis vulgaris on the trunk, limbs or scalp (except for emollients and non-medicated shampoos) within 2 weeks prior to Day 0 (Visit 1)
- •Planned initiation of, or changes to, concomitant medication that could affect psoriasis vulgaris (e.g., betablockers, antimalarials, lithium, ACE inhibitors) during the study
- •Oral calcium supplements, vitamin D supplements, bisphosphonates or calcitonin within 4 weeks prior to SV
- •Note: Stable doses of oral vitamin D supplementation ≤400 IU/day is permitted provided there are no dose adjustments during the study period
- •Planned initiation of, or changes to concomitant medication that could affect calcium metabolism (e.g. antacids, thiazide and/or loop diuretics, antiepileptics) during the study
- •Planned excessive exposure of area(s) to be treated with study medication to either natural or artificial sunlight (including tanning booths, sunlamps etc.) during the study
- •Oestrogen therapy (including contraceptives), antidepressant medications and any other medication known to affect cortisol levels or HPA axis integrity within 4 weeks prior to SV2
- •Cytochrome P450 3A4 (CYP 3A4) inducers (e.g., barbiturates, phenytoin, rifampicin) within 4 weeks prior to SV2
- •Systemic cytochrome P450 3A4 (CYP 3A4) inhibitors (e.g., ketoconazole, itraconazole, metronidazole) within 4 weeks prior to SV2
- •Topical cytochrome P450 3A4 (CYP 3A4) inhibitors (e.g., ketoconazole) within 2 weeks prior to SV2
- •Non-nocturnal sleep patterns (e.g. night shift workers)
- •Any of the following conditions, whether known or suspected:
- •depression and endocrine disorders (e.g. Cushing's disease, Addison's disease, diabetes mellitus) known to affect cortisol levels or HPA axis integrity
- •disorders of calcium metabolism associated with hypercalcaemia
- •cardiac disorders associated with abnormal QT intervals or rhythm disturbances including clinically significant bradycardia or tachycardia
- •severe renal insufficiency
- •severe hepatic disorders
- •Any clinically significant abnormality following blood pressure/heart rate measurement or review of screening laboratory tests (blood and spot urine samples) collected at SV2
- •Any clinically significant abnormality following physical examination at SV1
- •Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis
- •Any of the following conditions present on the study treatment areas (trunk, limbs and scalp): viral (e.g., herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, ulcers and wounds
- •Other inflammatory skin disorders (e.g. seborrhoeic dermatitis and contact dermatitis) that may confound the evaluation of psoriasis vulgaris
- •Current participation in any other interventional clinical trial
- •Previously enrolled in this trial
- •Known or suspected of not being able to comply with the trial protocol (e.g., alcoholism, drug dependency or psychotic state)
- •Females who are pregnant, wishing to become pregnant during the study or who are breast-feeding
研究组 & 干预措施
LEO 90100
Experimental
干预措施: LEO 90100 (Drug)
结局指标
主要结局
Change in Albumin-corrected Serum Calcium From Baseline to Day 28
时间窗: Baseline and Day 28
The effect of LEO 90100 on calcium metabolism was evaluated based on change in albumin-corrected serum calcium from Baseline to Day 28.
Change in 24-hour Urinary Calcium Excretion From Baseline to Day 28
时间窗: Baseline and Day 28
The effect of LEO 90100 on calcium metabolism was evaluated based on change in 24-hour urinary calcium excretion from Baseline to Day 28 in 24-hour.
Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After Adrenocorticotrophic Hormone-challenge (ACTH-challenge)
时间窗: Day 28
HPA-axis testing by means of the rapid standard-dose cosyntropin test (ACTH-challenge test) for detection of adrenal suppression.
Change in 24-hour Urinary Calcium:Creatinine Ratio From Baseline to Day 28
时间窗: Baseline and Day 28
The effect of LEO 90100 on calcium metabolism was evaluated based on change in urinary calcium:creatinine ratio from Baseline to Day 28.
次要结局
- Number of Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 and 60 Minutes After ACTH-challenge at Day 28(Day 28)
- Change in Serum Phosphate From Baseline to Day 28(Baseline and Day 28)
- Pharmacokinetic Evaluation AUCinf(4 weeks / 28 days)
- Change in Heart Rate From Baseline to Day 28(Baseline and Day 28)
- Pharmacokinetic Evaluation Cmax(4 weeks / 28 days)
- Pharmacokinetic Evaluation AUClast(4 weeks / 28 days)
- Pharmacokinetic Evaluation Tmax(4 weeks / 28 days)
- Number of Participants With an Adverse Drug Reaction (ADR)(Baseline to Day 28)
- Change in 24-hour Urinary Phosphate Excretion From Baseline to Day 28(Baseline and Day 28)
- Number of Subjects Who Discontinued From the Study(Baseline to Day 28)
- Change in Plasma Parathyroid Hormone (PTH) From Baseline to Day 28(Baseline and Day 28)
- Change in Blood Pressure From Baseline to Day 28(Baseline and Day 28)
- Pharmacokinetic Evaluation T1/2(4 weeks / 28 days)
- Efficacy Evaluation(4 weeks I 28 days and End of treatment)
- Change in Urinary Phosphate: Creatinine Ratio From Baseline to Day 28(Baseline and Day 28)
- Change in Serum Alkaline Phosphatase (ALP) From Baseline to Day 28(Baseline and Day 28)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
1 期
A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)Keratoconjunctivitis SiccaNCT00851734Lux Biosciences, Inc.35
Unknown
1 期
LEAC-102 for Advanced Colorectal CancerAdvanced Colorectal CancerNCT02826837Taiwan Leader Biotech Corp.30
已完成
2 期
URO-902 in Female Subjects With Overactive Bladder and Urge Urinary IncontinenceOveractive Bladder With Urge Urinary IncontinenceNCT04211831Urovant Sciences GmbH80
已完成
2 期
A Study of NOE-115 in Women With Vasomotor Symptoms Due to MenopauseMenopause SyndromeHot FlashesMenopauseNCT06385795Noema Pharma AG40
进行中（未招募）
2 期
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)FSHDFSHD1FSHD2FMDFMD2Fascioscapulohumeral Muscular DystrophyFascioscapulohumeral Muscular Dystrophy Type 1Fascioscapulohumeral Muscular Dystrophy Type 2Dystrophies, Facioscapulohumeral MuscularDystrophy, Facioscapulohumeral MuscularFacioscapulohumeral Muscular Dystrophy 1Facioscapulohumeral Muscular Dystrophy 2Facio-Scapulo-Humeral DystrophyAtrophy, FacioscapulohumeralAtrophies, FacioscapulohumeralFacioscapulohumeral AtrophyMuscular DystrophiesMuscular Dystrophy, FacioscapulohumeralFSH Muscular DystrophyLandouzy Dejerine DystrophyLandouzy-Dejerine Muscular DystrophyDystrophies, Landouzy-DejerineDystrophy, Landouzy-DejerineLandouzy-Dejerine SyndromeMuscular Dystrophy, Landouzy DejerineFSHProgressive Muscular DystrophyNCT06547216Avidity Biosciences, Inc.84